Losartan Potassium Tablets Recalled Due to Impurity Presence
Golden State Medical Supply Inc. is recalling Losartan Potassium Tablets 25 mg because FDA labs found an impurity above acceptable levels.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric, particularly given the presence of a nitrosamine impurity above acceptable limits.
Plain-English summary
Golden State Medical Supply Inc. is recalling Losartan Potassium Tablets USP 25 mg, 90-count bottles (NDC 60429-316-90). The recall involves 64,362 HDPE bottles distributed to accounts in Illinois, Michigan, Minnesota, Pennsylvania, Tennessee, and Texas, including two U.S. government and one Veterans Affairs account.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. FDA laboratory testing confirmed the presence of the impurity N-Methylnitrosobutyric acid (NMBA) in the finished product at levels above the interim acceptable daily intake limit at the manufacturer.
Patients and healthcare providers should stop using the affected lots and contact their healthcare provider for alternative treatment. The affected lot codes are GS015172 (exp 06/2019), GS017634 (exp 02/2020), GS017653 (exp 02/2020), GS017980 (exp 02/2020), GS017276 (exp 02/2020), GS017045 (exp 02/2020), and GS016726 (exp 02/2020).
The recalled product
- Product
- Losartan Potassium Tablets USP 25 mg 90 count bottle NDC 60429-316-90 Rx only GSMS Incorporated
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 64,362
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- GS015172 exp 06/2019 GS017634 02/2020
- GS017653 exp 02/2020
- GS017980 exp 02/2020
- GS017276 exp 02/2020
- GS017045 exp 02/2020
- GS016726 exp 02/2020
Distribution
Part of a larger recall action
This product is one of 5 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · Golden State Medical Supply Inc.
See all →- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighBaclofen tablet bottles recalled over the presence of foreign tablets
FDA (Drugs) · 2025-12-24
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17